• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks

    NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology

    Gabrielle Lakusta
    Dec. 28, 2018 09:08AM PST
    Medical Device Investing

    NeuroMetrix (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,159,835 titled “Detecting cutaneous electrode peeling using electrode-skin impedance.” The patent covers novel methods of monitoring electrode-skin contact for safe delivery of electrical stimulation while the user is sleeping. As quoted in the press release: NeuroMetrix now has 10 …

    NeuroMetrix (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,159,835 titled “Detecting cutaneous electrode peeling using electrode-skin impedance.” The patent covers novel methods of monitoring electrode-skin contact for safe delivery of electrical stimulation while the user is sleeping.

    As quoted in the press release:

    NeuroMetrix now has 10 issued U.S. utility patents covering the Quell® Wearable Pain Relief Technology™.

    “We are pleased to have received this latest patent, which covers a key technology that allows chronic pain sufferers to use Quell for pain relief at night,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “Making Quell therapy available to our users overnight is important as many report that pain interferes with their sleep. More than thirty-thousand of our customers have used Quell while sleeping.  Quell is the only over-the-counter transcutaneous electrical nerve stimulator that is cleared by the FDA for overnight use.”

    Click here to read the full press release.

    nasdaq:nuro
    The Conversation (0)

    Go Deeper

    AI Powered
    Stethoscope connected to a phone with medical data overlay.

    Top 5 Small-cap Medical Device Stocks (Updated January 2025)

    Cardiex Limited (ASX:CDX)

    Cardiex Limited

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×